OPKO Health Inc
OPK1.385USD
-0.015-1.07%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.06BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über OPKO Health Inc Unternehmen
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
OPKO Health Inc Informationen
BörsenkürzelOPK
Name des UnternehmensOPKO Health Inc
IPO-datumNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Anzahl der mitarbeiter2997
WertpapierartOrdinary Share
GeschäftsjahresendeNov 02
Addresse- -
Stadt- -
BörseNASDAQ Global Select Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelOPK
IPO-datumNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Führungskräfte von OPKO Health Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
Nach RegionUSD
Name
Umsatz
Anteil
United States
114.88M
73.26%
Chile
16.00M
15.83%
Ireland
11.74M
11.61%
Spain
6.72M
6.65%
Mexico
6.30M
6.23%
Andere
-54.55M
-13.59%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.97%
Hsiao (Jane H)
4.32%
Andere
50.53%
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.97%
Hsiao (Jane H)
4.32%
Andere
50.53%
Aktionärstypen
Aktionäre
Anteil
Corporation
37.85%
Investment Advisor
12.39%
Individual Investor
10.57%
Hedge Fund
7.62%
Investment Advisor/Hedge Fund
5.83%
Research Firm
1.05%
Bank and Trust
0.16%
Pension Fund
0.12%
Family Office
0.02%
Andere
24.39%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
455
208.86M
27.21%
-55.45M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Frost Gamma Investments Trust
220.16M
27.74%
+360.00K
+0.16%
Sep 30, 2025
Rubric Capital Management LP
47.79M
6.02%
-915.40K
-1.88%
Jun 30, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
The Vanguard Group, Inc.
38.16M
4.81%
+8.74M
+29.70%
Jun 30, 2025
Hsiao (Jane H)
33.13M
4.17%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
28.22M
3.55%
+3.45M
+13.93%
Jun 30, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
10.42M
1.31%
+2.00M
+23.68%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.55%
SPDR S&P Health Care Services ETF
0.49%
VanEck Israel ETF
0.15%
Humankind US Stock ETF
0.11%
iShares U.S. Healthcare Providers ETF
0.11%
Goldman Sachs Innovate Equity ETF
0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.55%
SPDR S&P Health Care Services ETF
Anteil0.49%
VanEck Israel ETF
Anteil0.15%
Humankind US Stock ETF
Anteil0.11%
iShares U.S. Healthcare Providers ETF
Anteil0.11%
Goldman Sachs Innovate Equity ETF
Anteil0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.06%
iShares Biotechnology ETF
Anteil0.05%
iShares Russell 2000 Value ETF
Anteil0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
